Table 2.
Relationship between each variable and development of MRONJ (per jaw).
| Variable | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| p-value | HR | 95% CI | p-value | HR | 95% CI | ||
| Age (years) | 0.083 | 1.028 | 0.996–1.060 | 0.319 | 1.019 | 0.983–1.056 | |
| Sex | Female vs. male | 0.893 | 1.051 | 0.509–2.172 | |||
| Primary site | upper vs. lower jaw | 0.249 | 1.508 | 0.750–3.031 | |||
| Smoking | (−) vs. (+) | 0.302 | 0.535 | 0.163–1.756 | |||
| Diabetes | (−) vs. (+) | 0.739 | 1.195 | 0.420–3.402 | |||
| Corticosteroid | (−) vs. (+) | 0.617 | 0.738 | 0.224–2.428 | |||
| Leukocytes (102/μL) | 0.996 | 1.000 | 0.984–1.016 | ||||
| Albumin (g/dL) | 0.379 | 0.813 | 0.512–1.290 | ||||
| Sort of BMA | Bisphosphonate vs. denosumab | 0.317 | 1.351 | 0.750–2.436 | |||
| Duration of administration (months) | 0.143 | 1.008 | 0.997–1.019 | 0.010 | 1.016 | 1.004–1.029 | |
| Number of teeth | 0.066 | 0.920 | 0.842–1.005 | 0.033 | 0.898 | 0.813–0.991 | |
| Symptom of local infection | (−) vs. (+) | < 0.001 | 8.865 | 4.397–17.875 | < 0.001 | 7.900 | 3.605–17.311 |
| Teeth that can be a source of infection | (−) vs. (+) | 0.004 | 3.125 | 1.450–6.737 | 0.047 | 2.381 | 1.013–5.600 |
| Tooth extraction during BMA therapy | (−) vs. (+) | 0.067 | 2.460 | 0.940–6.439 | 0.610 | 1.298 | 0.477–3.534 |
*Cox regression analysis.
Teeth that can be a source of infection:
periapical lesion (> 3 mm) or aloveolar bone loss (> 1/2) or probing pocket depth (> 4 mm).